Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer vaccines.

R F Rousseau1, C Hirschmann-Jax, S Takahashi

  • 1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.

Hematology/Oncology Clinics of North America
|October 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

A whole blood model of thrombocytopenia that controls platelet count and hematocrit.

Annals of hematology·2016
Same author

Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor.

Leukemia & lymphoma·2016
Same author

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.

British journal of cancer·2014
Same author

Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD.

Bone marrow transplantation·2014
Same author

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.

Bone marrow transplantation·2013
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Generating an anticancer immune response in vivo shows promise for cancer treatment. Further research is needed to establish the clinical value of tumor vaccines, especially in solid tumors.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • In vivo generation of anticancer immune responses is a key area of cancer research.
  • Limited studies exist on immune responses in hematologic malignancies, but this is expected to increase.
  • The clinical effectiveness and duration of current immunotherapeutic approaches in solid tumors remain largely unknown.

Purpose of the Study:

  • To review the current landscape of generating anticancer immune responses in vivo.
  • To discuss the potential and challenges of tumor vaccines in clinical practice.
  • To highlight the need for further research and clinical trials.

Main Methods:

  • Review of existing literature on in vivo anticancer immune response generation.
  • Analysis of studies focusing on hematologic and solid tumors.

Related Experiment Videos

  • Discussion of the molecular basis of immune response and cancer immune evasion.

    • Main Results:

    • While survival benefits are documented with tumor immunization, no randomized clinical trial has been fully convincing.
    • Effectiveness and duration of immune responses in solid tumors are not yet established.
    • Hematologic malignancy research is expected to expand rapidly.

    Conclusions:

    • Tumor vaccines are expected to complement, not replace, conventional cancer therapies in the near future.
    • Improved understanding of molecular immunology and cancer defenses will drive progress.
    • Further clinical validation is crucial for widespread adoption of immunotherapies.